Earnings summaries and quarterly performance for ARROWHEAD PHARMACEUTICALS.
Executive leadership at ARROWHEAD PHARMACEUTICALS.
Board of directors at ARROWHEAD PHARMACEUTICALS.
Research analysts who have asked questions during ARROWHEAD PHARMACEUTICALS earnings calls.
LI
Luca Issi
RBC Capital Markets
6 questions for ARWR
Also covers: ADVM, ALLO, ALNY +12 more
ET
Edward Tenthoff
Piper Sandler Companies
5 questions for ARWR
Also covers: ARVN, CAPR, CLRB +14 more
AN
Andrea Newkirk
Goldman Sachs
4 questions for ARWR
Also covers: ABCL, ALKS, DAWN +9 more
Jason Gerberry
Bank of America Merrill Lynch
4 questions for ARWR
Also covers: ALKS, AMPH, AXSM +21 more
Prakhar Agrawal
Cantor Fitzgerald
4 questions for ARWR
Also covers: ARDX, MDGL, ROIV +4 more
BS
Brendan Smith
Stifel, Nicolaus & Company, Incorporated
3 questions for ARWR
Also covers: ABCL, ABSI, AZTA +19 more
Joseph Thome
TD Cowen
3 questions for ARWR
Also covers: ALKS, AMLX, ARDX +12 more
MR
Maurice Raycroft
Jefferies Financial Group
3 questions for ARWR
Also covers: ABEO, AFMD, ALNY +14 more
Mayank Mamtani
B. Riley Securities
3 questions for ARWR
Also covers: AGEN, ALT, CGTX +18 more
Patrick Trucchio
H.C. Wainwright & Co.
3 questions for ARWR
Also covers: ALT, ATAI, CMPS +13 more
EW
Emmanuel Walter
Leerink Partners
2 questions for ARWR
GA
Gina Ahn
Bank of America
2 questions for ARWR
ME
Madison El-Saadi
B. Riley
2 questions for ARWR
MF
Mani Foroohar
Leerink Partners
2 questions for ARWR
Also covers: ADVM, ALNY, BBIO +9 more
MR
Maury Raycroft
Jefferies
2 questions for ARWR
Also covers: ABEO, ALNY, BCRX +11 more
MU
Michael Ulz
Morgan Stanley
2 questions for ARWR
Also covers: ALNY, FATE, GUTS +8 more
MU
Mike Ulz
Morgan Stanley
2 questions for ARWR
Also covers: IONS, YMAB
PT
Patrick Trujillo
H.C. Wainwright
2 questions for ARWR
WP
William Pickering
Sanford C. Bernstein & Co.
2 questions for ARWR
Also covers: ALLO, NTLA, REGN +1 more
AT
Andrea Tan
Goldman Sachs
1 question for ARWR
Also covers: ABCL, DAWN, INSM +3 more
BS
Brian Swanson
Leerink Partners
1 question for ARWR
DL
David Lebowitz
Citigroup Inc.
1 question for ARWR
Also covers: ALNY, ASND, BPMC +11 more
ET
Edward Tenthof
Piper Sandler
1 question for ARWR
EM
Eliana Merle
UBS
1 question for ARWR
Also covers: ALNY, APLS, ARVN +17 more
EM
Eliana Merrill
UBS
1 question for ARWR
EM
Ellie Merle
UBS Group AG
1 question for ARWR
Also covers: ALNY, ALT, ARVN +12 more
Farzin Haque
Jefferies
1 question for ARWR
Also covers: ABEO, AUPH, NTLA +3 more
JF
Jasmine Fels
UBS
1 question for ARWR
Also covers: ALT, APLS, BMRN
ME
Madison Elsaadi
B. Riley Securities
1 question for ARWR
Also covers: ETON
MF
Mani Furuhar
Leerink Partners
1 question for ARWR
MK
Mary Kate Davis
Bank of America
1 question for ARWR
Also covers: EDIT
Recent press releases and 8-K filings for ARWR.
Arrowhead Pharmaceuticals, Inc. Issues Convertible Senior Notes
ARWR
Debt Issuance
Convertible Preferred Issuance
- Arrowhead Pharmaceuticals, Inc. has issued $700,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2032.
- The Notes, issued on January 12, 2026, will mature on January 15, 2032, and do not bear regular interest.
- The Company has the option to redeem the Notes on or after January 16, 2029, provided certain stock price conditions are met.
- Noteholders can require the Company to repurchase their Notes upon the occurrence of a "Fundamental Change", which includes specific corporate events or de-listing.
2 days ago
Arrowhead Pharmaceuticals Details Commercial Launch and Pipeline Progress
ARWR
Product Launch
New Projects/Investments
- Arrowhead Pharmaceuticals reported a market capitalization of approximately $9 billion and significant financial resources, including $920 million in cash and investments as of its last filing, supplemented by $400 million from Sarepta and Novartis, and $930 million from recent offerings.
- The company commercially launched Rudemplo (formerly Plozasiran) in late November 2025 in the US, Canada, and China for familial chylomicronemia syndrome (FCS), with phase 3 data for the broader severe hypertriglyceridemia (SHTG) market expected in Q3 2026 and a launch in 2027.
- Arrowhead is progressing a diverse pipeline, including Zodasiran for HoFH (expected launch 2028), ARO-Dimer-PA for mixed hyperlipidemia with initial clinical data anticipated by the end of Q3 2026, and obesity candidates ARO-INHBE and ARO-ALK7 with additional data throughout 2026.
- The first wholly owned CNS candidate, ARO-MAPT, targeting Alzheimer's and tauopathies, is in a Phase 1/2 study, with initial readouts expected by the end of Q3 2026, which could validate the broader CNS platform.
2 days ago
Arrowhead Pharmaceuticals Provides Update on Rudemplo Launch, Pipeline Progress, and Financial Position
ARWR
Product Launch
New Projects/Investments
Guidance Update
- Arrowhead Pharmaceuticals launched Rudemplo (formerly Plozasiran) in November 2025 in the US, Canada, and China for familial chylomicronemia syndrome (FCS). Phase 3 studies for its expansion into the severe hypertriglyceridemia (SHTG) market are expected to read out in Q3 2026, with a launch planned for 2027.
- The company maintains a strong financial position with approximately $920 million in cash and investments, augmented by $200 million from Sarepta, $200 million from Novartis, and $930 million from recent offerings.
- Promising early data for obesity candidates ARO-INHBE and ARO-ALK7 showed doubled weight loss in obese diabetic patients when ARO-INHBE was combined with tirzepatide. The company plans to initiate Phase 2B studies and intends to keep these programs wholly owned.
- Upcoming clinical milestones include initial readouts for the CNS candidate ARO-MAPT by the end of Q3 2026 and the first clinical readout for ARO-Dimer-PA in H2 2026.
2 days ago
Arrowhead Pharmaceuticals Provides Business Update and Pipeline Milestones
ARWR
Product Launch
New Projects/Investments
- Arrowhead Pharmaceuticals (ARWR) reported a market capitalization of approximately $9 billion with 136 million shares outstanding as of Friday, January 9, 2026. The company has substantial financial resources, including ~$920 million in cash and investments from its last filing, an additional $200 million from Sarepta (invoiced), $200 million from Novartis (received), and $930 million from recent offerings, with another $50 million expected from Sarepta in February 2026.
- The company's first RNAi-based medicine, Rudemplo (formerly Plozasiran), was launched in the US, Canada, and China towards the end of November 2025 for familial chylomicronemia syndrome (FCS). Rudemplo is priced at $60,000 for FCS patients and is expected to be priced similarly for severe hypertriglyceridemia (SHTG), a market estimated at 3 to 3.5 million people in the US.
- Key upcoming milestones in 2026 include Phase 3 readout for Rudemplo in SHTG in Q3 2026 with an SNDA filing in Q4 2026. Initial clinical data for ARO-Dimer-PA, a novel dual-targeting therapy for mixed hyperlipidemia, is expected towards the end of Q3 2026, following dosing initiation in January 2026.
- Early data from obesity candidates ARO-INHBE and ARO-ALK7 show promising results, with ARO-INHBE demonstrating a 15.6% reduction in visceral fat at week 24 and doubling weight loss when combined with tirzepatide in obese diabetic patients.
- Initial readouts for ARO-MAPT, the first wholly-owned CNS candidate for Alzheimer's and tauopathies, are also anticipated towards the end of Q3 2026.
2 days ago
Arrowhead Pharmaceuticals Prices Upsized Offerings of Notes, Stock, and Warrants
ARWR
Debt Issuance
Equity Offering
- Arrowhead Pharmaceuticals priced upsized offerings on January 7, 2026, including $625,000,000 aggregate principal amount of 0.00% convertible senior notes due 2032.
- The company also priced an equity offering of 3,100,776 shares of common stock at $64.50 per share and pre-funded warrants for up to 1,550,387 shares at $64.499 per warrant.
- Underwriters fully exercised their option to purchase an additional 456,116 shares of common stock on January 8, 2026, with the equity offering expected to generate approximately $216.6 million in net proceeds.
- The convertible notes have an initial conversion price of approximately $87.07 per share, representing a 35.0% premium over the common stock offering price.
6 days ago
Arrowhead Pharmaceuticals Prices Upsized Offerings
ARWR
Debt Issuance
Convertible Preferred Issuance
New Projects/Investments
- Arrowhead Pharmaceuticals priced concurrent public offerings, including $625,000,000 aggregate principal amount of 0.00% convertible senior notes due 2032 and 3,100,776 shares of common stock at $64.50 per share.
- The note offering size was upsized from $500,000,000, and the notes have an initial conversion price of approximately $87.07 per share, representing a 35.0% premium over the common stock offering price.
- Estimated net proceeds are approximately $608.2 million from the note offering and $188.3 million from the common stock offering.
- Arrowhead intends to use approximately $42.8 million of the note proceeds for capped call transactions and the remainder for general corporate purposes, including working capital, research and development, and clinical trial expenditures.
7 days ago
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO in China
ARWR
Product Launch
New Projects/Investments
- Arrowhead Pharmaceuticals announced the Chinese National Medical Products Administration (NMPA) approval of REDEMPLO® (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS) in China.
- This approval triggers a $10 million milestone payment to be paid by Sanofi to Arrowhead's subsidiary Visirna Therapeutics.
- Sanofi will market REDEMPLO in Greater China, having purchased the rights from Visirna in 2025.
- This marks the third regulatory approval for REDEMPLO, following approvals by the U.S. FDA and Health Canada, with the U.S. launch occurring in November 2025.
8 days ago
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
ARWR
Debt Issuance
New Projects/Investments
- Arrowhead Pharmaceuticals announced its intention to offer $500 million aggregate principal amount of convertible senior notes due 2032 and $200 million of common stock in separate public offerings.
- The company expects to grant the underwriters options to purchase up to an additional $75 million in notes and $30 million of common stock.
- The net proceeds from these offerings are intended for general corporate purposes, including working capital, capital expenditures, research and development, clinical trial expenditures, and preparation for potential commercial launches.
- A portion of the net proceeds from the note offering will be used to fund capped call transactions, which are expected to reduce potential dilution to Arrowhead's common stock upon any conversion of the notes.
Jan 6, 2026, 11:14 PM
Arrowhead Pharmaceuticals Announces Interim Clinical Data for Obesity Candidates ARO-INHBE and ARO-ALK7
ARWR
New Projects/Investments
- Arrowhead Pharmaceuticals, Inc. announced interim results from its Phase 1/2a clinical trials for ARO-INHBE and ARO-ALK7 on January 6, 2026.
- ARO-INHBE in combination with tirzepatide achieved -9.4% weight loss at week 16 in obese patients with type 2 diabetes, representing an approximately two-fold improvement versus tirzepatide alone, and demonstrated approximately three-fold improvements in visceral fat (-23.2%), total fat (-15.4%), and liver fat (-76.7%) reductions.
- ARO-INHBE monotherapy led to a mean visceral fat reduction of -9.9% (single dose, week 16) and -15.6% placebo adjusted (two doses, week 24), along with a 3.6% increase in total lean tissue.
- ARO-ALK7 monotherapy achieved a mean reduction of -88% in ALK7 mRNA and a -14.1% placebo-adjusted visceral fat reduction (single dose, week 8). Both investigational therapeutics were generally well tolerated in their respective studies.
Jan 6, 2026, 9:05 PM
Arrowhead Pharmaceuticals Reports Interim Results for Obesity Candidates ARO-INHBE and ARO-ALK7
ARWR
New Projects/Investments
- Arrowhead Pharmaceuticals announced interim results from Phase I and II studies for its obesity candidates, ARO-INHBE and ARO-ALK7.
- ARO-INHBE combined with tirzepatide resulted in a 9.4% mean weight loss at week 16 in obese diabetic patients, which doubled the 4.8% seen with tirzepatide monotherapy. This combination also led to significant reductions in visceral fat (-23.2%), total fat (-15.4%), and liver fat (-76.7%).
- ARO-ALK7 achieved a mean reduction of 88% ALK7 mRNA and a 14% placebo-adjusted reduction in visceral fat after a single monotherapy dose at week eight, demonstrating the first human RNAi-mediated knockdown targeting adipocytes.
- The company plans to expand existing studies, initiate Phase II studies for both candidates, and continue developing its obesity pipeline with new targets and combination therapies.
Jan 6, 2026, 4:30 PM
Fintool News
In-depth analysis and coverage of ARROWHEAD PHARMACEUTICALS.
Quarterly earnings call transcripts for ARROWHEAD PHARMACEUTICALS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more